TC-6987

TC-6987 is a small molecule drug originally developed by Targacept and later associated with Catalyst Biosciences. It acts as a selective modulator of the alpha7 neuronal nicotinic acetylcholine receptor (α7 nAChR), functioning as an open channel stabilizer. The drug was investigated for its anti-inflammatory and antioxidant properties in preclinical models and advanced to Phase 2 clinical trials for mild to moderate asthma and type 2 diabetes mellitus. In animal studies, TC-6987 demonstrated reductions in plasma glucose, triglycerides, HbA1c, and TNF-alpha levels—suggesting potential benefits in metabolic control and inflammation reduction. Despite these findings, development for both asthma and type 2 diabetes was discontinued after Phase 2 trials[1][4][5][7].

Other names

1196701-27-5(2S,3R)-N-(2-(3-pyridinylmethyl)-1-azabicyclo(2.2.2)oct-3-yl)-3,5-difluorobenzamide